Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SNDX · as of Sep 30, 2025
Ownership Breakdown
247
Institutional Holders
▲ 12 vs Q2
$1.56B
Total Inst. Value
▲ $604.79M vs Q2
88.61M
Shares Outstanding
freeFloat 89.80%
101.31M
13F Shares Held
▼ 447,533 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SNDX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 8.63M | 9.99% | 9.99% | $132.70B | Nov 12, 2025 | ▼ 1.83M |
KYNAM CAPITAL MANAGEMENT, LP pharmaceutical preparations | 8.52M | 9.87% | 9.87% | $131.08B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 5.49M | 6.35% | 6.35% | $84.41B | Nov 14, 2025 | ▼ 310.8K |
VANGUARD GROUP INC pharmaceutical preparations | 5.14M | 5.95% | 5.95% | $79.06B | Nov 7, 2025 | ▲ 104.7K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 4.26M | 4.93% | 4.93% | $65.46B | Nov 14, 2025 | ▲ 2.13M |
STATE STREET CORP pharmaceutical preparations | 3.85M | 4.46% | 4.46% | $59.29B | Nov 14, 2025 | ▲ 410.8K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 3.70M | 4.28% | 4.28% | $56.89B | Feb 3, 2026 | ▼ 141.1K |
EVERSEPT PARTNERS, LP pharmaceutical preparations | 3.47M | 4.02% | 4.02% | $53.34B | Nov 14, 2025 | ▼ 598.0K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 3.31M | 3.84% | 3.84% | $50.95B | Nov 14, 2025 | ▲ 1.88M |
KINGDON CAPITAL MANAGEMENT, L.L.C. pharmaceutical preparations | 2.50M | 2.90% | 2.90% | $38.46B | Nov 14, 2025 | ▲ 400.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+11.24M shares2
New Positions
first time holders18
Decreased
−7.10M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.14M
+11.24M / −7.10M
Net new holders
+11
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SNDX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Goldan Keith A. Chief Financial Officer | Jun 1, 2026 | Sale | 1,177 | $18.99 | $22.4K | 139.3K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Jun 1, 2026 | Sale | 6,847 | $18.99 | $130.0K | 484.8K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 9, 2026 | Sale | 17,159 | $21.03 | $360.8K | 491.7K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 9, 2026 | Sale | 3,410 | $21.03 | $71.7K | 140.4K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 144,600 | — | — | 516.3K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 6, 2026 | Sale | 7,412 | $20.62 | $152.8K | 508.8K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 440,000 | $20.43 | $8.99M | 440.0K | Form 4 ↗ |
Metzger Michael A Chief Executive Officer | Feb 4, 2026 | Award | 73,000 | — | — | 371.7K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 4, 2026 | Award | 30,750 | — | — | 145.9K | Form 4 ↗ |
Goldan Keith A. Chief Financial Officer | Feb 6, 2026 | Sale | 2,082 | $20.62 | $42.9K | 143.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Syndax Pharmaceuticals, Inc. (SNDX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 10.20%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Syndax Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 8.63 million shares — equal to 9.99% of outstanding shares — as of September 30, 2025.
A total of 247 institutional investors currently hold SNDX stock, with a combined institutional value of approximately $1.56 billion as of the most recent 13F filing period.
Frequently asked questions
SNDX ownershipSyndax Pharmaceuticals, Inc. (SNDX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 9.99% stake. Company insiders hold 10.20%. Data sourced from SEC Form 13F as of September 30, 2025.